Vista Finance LLC Acquires 45 Shares of Medpace Holdings, Inc. $MEDP

Vista Finance LLC increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,158 shares of the company’s stock after buying an additional 45 shares during the period. Vista Finance LLC’s holdings in Medpace were worth $363,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Whittier Trust Co. increased its position in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after purchasing an additional 35 shares during the last quarter. PDS Planning Inc increased its position in Medpace by 1.5% in the second quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock worth $760,000 after purchasing an additional 35 shares during the last quarter. Benjamin Edwards Inc. increased its position in Medpace by 3.1% in the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company’s stock worth $366,000 after purchasing an additional 36 shares during the last quarter. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Finally, Assetmark Inc. increased its position in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total value of $4,800,000.00. Following the completion of the sale, the vice president directly owned 57,500 shares of the company’s stock, valued at $27,600,000. This represents a 14.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the company’s stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director directly owned 10,197 shares of the company’s stock, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock valued at $74,111,427 over the last quarter. 20.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have weighed in on MEDP. William Blair reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, July 23rd. Cowen cut shares of Medpace from a “buy” rating to a “sell” rating in a research report on Wednesday, July 23rd. Robert W. Baird boosted their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Mizuho boosted their price objective on shares of Medpace from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Medpace in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Medpace currently has a consensus rating of “Reduce” and a consensus target price of $430.60.

Medpace Trading Up 1.3%

Shares of MEDP opened at $528.07 on Friday. The firm has a market capitalization of $14.84 billion, a P/E ratio of 39.26, a P/E/G ratio of 3.31 and a beta of 1.40. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $547.15. The firm has a fifty day moving average price of $492.23 and a 200-day moving average price of $382.32.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business’s revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.